Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 2/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17447728 | 1.00 | IDO1 (0.50) | IDO1TDO2MEN1MAPTCYP2C9 | |
| SCHEMBL3862491 | 1.00 | IDO1 (0.50) | IDO1TDO2MEN1MAPTCYP2C9 | |
| SCHEMBL8038938 | 0.85 | CFTR (0.46) | IDO1TDO2MEN1MAPTCYP2C9 | |
| SCHEMBL29930172 | 0.85 | CFTR (0.46) | IDO1TDO2MEN1MAPTCYP2C9 | |
| SCHEMBL23882867 | 0.84 | CYP3A4 (0.43) | IDO1TDO2MEN1MAPTCYP2C9 | |
| SCHEMBL11862016 | 0.84 | CYP11B1 (0.39) | IDO1TDO2MEN1MAPTCYP2C9 | |
| SCHEMBL22009838 | 0.84 | MEN1 (0.43) | IDO1TDO2MEN1MAPTCYP2C9 | |
| SCHEMBL11854000 | 0.84 | MLKL (0.41) | IDO1TDO2MEN1MAPTCYP2C9 | |
| SCHEMBL23882860 | 0.84 | CYP3A4 (0.43) | IDO1TDO2MEN1MAPTCYP2C9 | |
| SCHEMBL5377768 | 0.84 | TSHR (0.42) | IDO1TDO2MEN1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103420747-A | Synthetic method for olefin compounds | SUZHOU OST ADVANCED MATERIALS CO LTD | 2013-12-04 | — | — | CN | claimed |
| EP-2267064-B1 | Hydrophobic fluorinated polymer surfaces | UNIV MARBURG PHILIPPS (DE) | 2013-06-26 | — | — | EP | claimed |
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2859002-B1 | SILICON-BASED CROSS COUPLING AGENTS AND METHODS OF THEIR USE | UNIV PENNSYLVANIA (US) | 2020-12-30 | — | — | EP | disclosed |
| US-9850261-B2 | Silicon-based cross coupling agents and methods of their use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170210766-A1 | SILICON-BASED CROSS COUPLING AGENTS AND METHODS OF THEIR USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-27 | — | — | US | disclosed |
| US-9663476-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9499660-B2 | Silicon-based cross coupling agents and methods of their use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-11-22 | — | — | US | disclosed |
| CN-103420747-B | The synthetic method of alkenes compounds | 苏州奥索特新材料有限公司 | 2016-07-06 | — | — | CN | disclosed |
| WO-2016011231-A1 | SILICON-BASED CROSS COUPLING AGENTS AND METHODS OF THEIR USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-01-21 | — | — | WO | disclosed |
| EP-2947067-A1 | Glycine transporter-1 inhibitors | Amgen, Inc (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20070194468-A1 | Method of preparing organomagnesium compounds | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2007-08-23 | — | — | US | disclosed |
| CN-1930116-A | Chiral tertiary aminoalkylnaphthols | UNIV HONG KONG POLYTECHNIC (HK) | 2007-03-14 | — | — | CN | disclosed |
| EP-1727783-A1 | CHIRAL TERTIARY AMINOALKYLNAPHTHOLS | The Hong Kong Polytechnic University (CN) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005087707-A1 | CHIRAL TERTIARY AMINOALKYLNAPHTHOLS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2005-09-22 | — | — | WO | disclosed |
| EP-0003923-B1 | SUPPORT-ENZYME COMPLEXES AND METHOD FOR PREPARING THEM | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1982-10-20 | — | — | EP | disclosed |
| US-4258133-A | Enzyme-support complexes | RHONE-POULENC INDUSTRIES (FR) | 1981-03-24 | — | — | US | disclosed |
| EP-0003923-A1 | Support-enzyme complexes and method for preparing them | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1979-09-05 | — | — | EP | disclosed |
| US-3959475-A | ANTIDEPRESSANT, TRANQUILIZER, ANALGESIC | AMERICAN HOECHST CORPORATION (US) | 1976-05-25 | — | — | US | disclosed |
| US-3957828-A | 3-Aminoalkyl-1,3-dihydro-3-phenylspiro[isobenzofurans] | AMERICAN HOECHST CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210766-A1 | SILICON-BASED CROSS COUPLING AGENTS AND METHODS OF THEIR USE | RAD51, CA1, DCLRE1A | IDO1 3098/4885TDO2 3205/4885MEN1 1320/4885 |
| US-20070194468-A1 | Method of preparing organomagnesium compounds | SCLY, LIG3, LIG4 | IDO1 220/4885TDO2 1539/4885MEN1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.